{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T02:57:26Z","timestamp":1792205846872,"version":"4.4.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100007861","name":"University of Gondar","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007861","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"DOI":"10.1186\/s12936-024-05082-y","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T10:04:05Z","timestamp":1725012245000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Therapeutic efficacy and safety of artemether-lumefantrine combination therapy for the treatment of uncomplicated Plasmodium falciparum malaria at Teda Health Centre, Northwest Ethiopia, 2022\/23"],"prefix":"10.1186","volume":"23","clinical-trial-number":[{"clinical-trial-number":"pactr202309773069812","registry":"10.18810\/pactr"}],"author":[{"given":"Dagmawi","family":"Woldesenbet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meseret","family":"Birhanie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aberham","family":"Abere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayalew Jejaw","family":"Zeleke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Migbaru Keffale","family":"Bezabih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muluken","family":"Semaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menberu","family":"Wubetie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wagaw","family":"Abebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Tamene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalewayker","family":"Tegegne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,30]]},"reference":[{"key":"5082_CR1","volume-title":"World Malaria Report 2023","author":"WHO","year":"2023","unstructured":"WHO. World Malaria Report 2023. Geneva: World Health Organization; 2023."},{"key":"5082_CR2","volume-title":"Harrison's Principles of Internal Medicine","author":"NJ White","year":"2022","unstructured":"White NJ, Ashley EA. Malaria. In: Loscalzo J, Fauci A, Kasper D, Hauser S, Longo D, Jameson JL, editors. Harrison\u2019s Principles of Internal Medicine. 21st ed. New York: McGraw-Hill Education; 2022.","edition":"21"},{"key":"5082_CR3","unstructured":"Federal Republic Ethiopia Ministry of Health. National Malaria Elimination Programme (NMEP); 2021. https:\/\/www.mohgovet\/en\/initiatives-4-col\/National_Malaria_Elimination_Program?language_content_entity=en. Accessed 2 Aug 2022."},{"key":"5082_CR4","volume-title":"World malaria report 2022","author":"WHO","year":"2022","unstructured":"WHO. World malaria report 2022. Geneva: World Health Organization; 2022."},{"key":"5082_CR5","doi-asserted-by":"publisher","first-page":"5170550","DOI":"10.1155\/2022\/5170550","volume":"2022","author":"T Eshetu","year":"2022","unstructured":"Eshetu T, Muhamed B, Awol M, Kassa Z, Getu M, Derso A, et al. A retrospective analysis of malaria trends in Maksegnit Health Center over the last seven years, Northwest Ethiopia: 2014\u20132020. J Parasitol Res. 2022;2022:5170550.","journal-title":"J Parasitol Res"},{"key":"5082_CR6","first-page":"363","volume":"12","author":"Y Ewnetu","year":"2022","unstructured":"Ewnetu Y, Lemma W. Highland malaria transmission dynamics in space and time before pre-elimination era. Northwest Ethiopia J Epidemiol Glob Health. 2022;12:363\u201371.","journal-title":"Northwest Ethiopia J Epidemiol Glob Health"},{"key":"5082_CR7","volume-title":"Guidelines for malaria","author":"WHO","year":"2021","unstructured":"WHO. Guidelines for malaria. Geneva: World Health Organization; 2021."},{"key":"5082_CR8","unstructured":"Federal Republic Ethiopia Ministry of Health. Malaria diagnosis and treatment: a guideline for health workers in Ethiopia. Addis Ababa. 2004"},{"key":"5082_CR9","unstructured":"Federal Republic Ethiopia Ministry of Health. National Malaria Guidelines.4th Edn. Addis Ababa, Ethiopia; 2018."},{"key":"5082_CR10","doi-asserted-by":"publisher","first-page":"132","DOI":"10.4269\/ajtmh.15-0477","volume":"94","author":"AG Bayih","year":"2016","unstructured":"Bayih AG, Getnet G, Alemu A, Getie S, Mohon AN, Pillai DR. A unique Plasmodium falciparum Kelch 13 gene mutation in northwest Ethiopia. Am J Trop Med Hyg. 2016;94:132\u20135.","journal-title":"Am J Trop Med Hyg"},{"key":"5082_CR11","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-171038\/v1","author":"AA Alemayehu","year":"2021","unstructured":"Alemayehu AA, Castaneda-Mogollon D, Tesfa H, Getie S, Mohon AN, Balasingam N, et al. Expansion of the Plasmodium falciparum Kelch 13 R622I mutation in Northwest Ethiopia. Res Square. 2021. https:\/\/doi.org\/10.21203\/rs.3.rs-171038\/v1.","journal-title":"Res Square"},{"key":"5082_CR12","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.66277","volume":"10","author":"BH Stokes","year":"2021","unstructured":"Stokes BH, Dhingra SK, Rubiano K, Mok S, Straimer J, Gn\u00e4dig NF, et al. Plasmodium falciparum K13 mutations in Africa and Asia impact artemisinin resistance and parasite fitness. Elife. 2021;10: e66277.","journal-title":"Elife"},{"key":"5082_CR13","doi-asserted-by":"publisher","first-page":"6353","DOI":"10.1038\/s41467-022-33873-x","volume":"13","author":"PK Tumwebaze","year":"2022","unstructured":"Tumwebaze PK, Conrad MD, Okitwi M, Orena S, Byaruhanga O, Katairo T, et al. Decreased susceptibility of Plasmodium falciparum to both dihydroartemisinin and lumefantrine in northern Uganda. Nat Commun. 2022;13:6353.","journal-title":"Nat Commun"},{"key":"5082_CR14","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12936-024-04896-0","volume":"23","author":"C Bakari","year":"2024","unstructured":"Bakari C, Mandara CI, Madebe RA, Seth MD, Ngasala B, Kamugisha E, et al. Trends of Plasmodium falciparum molecular markers associated with resistance to artemisinins and reduced susceptibility to lumefantrine in Mainland Tanzania from 2016 to 2021. Malar J. 2024;23:71.","journal-title":"Malar J"},{"key":"5082_CR15","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s12936-021-03745-8","volume":"20","author":"A Abamecha","year":"2021","unstructured":"Abamecha A, Yilma D, Adissu W, Yewhalaw D, Abdissa A. Efficacy and safety of artemether\u2013lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Ethiopia: a systematic review and meta-analysis. Malar J. 2021;20:213.","journal-title":"Malar J"},{"key":"5082_CR16","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12936-018-2418-y","volume":"17","author":"N Scott","year":"2018","unstructured":"Scott N, Ataide R, Wilson DP, Hellard M, Price RN, Simpson JA, et al. Implications of population-level immunity for the emergence of artemisinin-resistant malaria: a mathematical model. Malar J. 2018;17:279.","journal-title":"Malar J"},{"key":"5082_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12936-021-03942-5","volume":"20","author":"C Nsanzabana","year":"2021","unstructured":"Nsanzabana C. Time to scale up molecular surveillance for anti-malarial drug resistance in sub-saharan Africa. Malar J. 2021;20:1\u20135.","journal-title":"Malar J"},{"key":"5082_CR18","volume-title":"Artemisinin and artemisinin-based combination therapy resistance: status report","author":"WHO","year":"2016","unstructured":"WHO. Artemisinin and artemisinin-based combination therapy resistance: status report. Geneva: World Health Organization; 2016."},{"key":"5082_CR19","volume-title":"Methods for surveillance of antimalarial drug efficacy","author":"WHO","year":"2009","unstructured":"WHO. Methods for surveillance of antimalarial drug efficacy. Geneva: World Health Organization; 2009."},{"key":"5082_CR20","unstructured":"Novartis Pharmaceuticals Corporation. COARTEM\u00ae (artemether and lumefantrine) tablets, for oral use. 2019."},{"key":"5082_CR21","unstructured":"Mondal H, Lotfollahzadeh S. 2024 Hematocrit. In: StatPearls Publishing [Internet]."},{"key":"5082_CR22","volume-title":"World malaria report 2019","author":"WHO","year":"2019","unstructured":"WHO. World malaria report 2019. Geneva: World Health Organization; 2019."},{"key":"5082_CR23","unstructured":"Thermo Fisher Scientific. MagMAX\u2122 DNA Multi-Sample Kit. 2016."},{"key":"5082_CR24","first-page":"103","volume":"72","author":"G Snounou","year":"2002","unstructured":"Snounou G. Genotyping of Plasmodium spp. nested PCR. Methods Mol Med. 2002;72:103\u201316.","journal-title":"Methods Mol Med"},{"key":"5082_CR25","unstructured":"WWARN. Agarose Gel Electrophoresis of msp1, msp2 and glurp. https:\/\/www.iddo.org\/procedure\/agarose-gel-electrophoresis-msp1-msp2-and-glurp. Accessed 15 Aug 2022."},{"key":"5082_CR26","unstructured":"WHO. Tools for monitoring antimalarial drug efficacy. https:\/\/www.who.int\/teams\/global-malaria-programme\/case-management\/drug-efficacy-and-resistance\/tools-for-monitoring-antimalarial-drug-efficacy. Accessed 15 Aug 2022."},{"key":"5082_CR27","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1186\/s12936-015-0826-9","volume":"14","author":"SK Mekonnen","year":"2015","unstructured":"Mekonnen SK, Medhin G, Berhe N, Clouse RM, Aseffa A. Efficacy of artemether\u2013lumefantrine therapy for the treatment of uncomplicated Plasmodium falciparum malaria in Southwestern Ethiopia. Malar J. 2015;14:317.","journal-title":"Malar J"},{"key":"5082_CR28","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s12936-020-03307-4","volume":"19","author":"A Abamecha","year":"2020","unstructured":"Abamecha A, Yilma D, Addisu W, El-Abid H, Ibenthal A, Noedl H, et al. Therapeutic efficacy of artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Chewaka District. Ethiopia Malar J. 2020;19:240.","journal-title":"Ethiopia Malar J"},{"key":"5082_CR29","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s12936-015-0775-3","volume":"14","author":"G Getnet","year":"2015","unstructured":"Getnet G, Fola AA, Alemu A, Getie S, Fuehrer H-P, Noedl H. Therapeutic efficacy of artemether\u2013lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Enfranze, north-west Ethiopia. Malar J. 2015;14:258.","journal-title":"Malar J"},{"key":"5082_CR30","doi-asserted-by":"publisher","first-page":"6958","DOI":"10.1073\/pnas.1001323107","volume":"107","author":"PD Crompton","year":"2010","unstructured":"Crompton PD, Kayala MA, Traore B, Kayentao K, Ongoiba A, Weiss GE, et al. A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarray. Proc Natl Acad Sci USA. 2010;107:6958\u201363.","journal-title":"Proc Natl Acad Sci USA"},{"key":"5082_CR31","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1111\/j.1365-3156.2006.01739.x","volume":"11","author":"MB Denis","year":"2006","unstructured":"Denis MB, Tsuyuoka R, Lim P, Lindegardh N, Yi P, Top SN, et al. Efficacy of artemether\u2013lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Cambodia. Trop Med Int Health. 2006;11:1800\u20137.","journal-title":"Trop Med Int Health"},{"key":"5082_CR32","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/1475-2875-10-231","volume":"10","author":"J Song","year":"2011","unstructured":"Song J, Socheat D, Tan B, Seila S, Xu Y, Ou F, et al. Randomized trials of artemisinin-piperaquine, dihydroartemisinin-piperaquine phosphate and artemether-lumefantrine for the treatment of multi-drug resistant falciparum malaria in Cambodia-Thailand border area. Malar J. 2011;10:231.","journal-title":"Malar J"},{"key":"5082_CR33","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/S1473-3099(21)00692-7","volume":"22","author":"TJ Peto","year":"2022","unstructured":"Peto TJ, Tripura R, Callery JJ, Lek D, Nghia HDT, Nguon C, et al. Triple therapy with artemether\u2013lumefantrine plus amodiaquine versus artemether\u2013lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial. Lancet Infect Dis. 2022;22:867\u201378.","journal-title":"Lancet Infect Dis"},{"key":"5082_CR34","first-page":"49","volume":"64","author":"A Konat\u00e9","year":"2018","unstructured":"Konat\u00e9 A, Barro-Kiki PCM, Angora KE, Bedia-Tanoh AV, Djohan V, Kassi KF, et al. Efficacy and tolerability of artesunate-amodiaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria at two sentinel sites across C\u00f4te d\u2019Ivoire. Ann Parasitol. 2018;64:49\u201357.","journal-title":"Ann Parasitol"},{"key":"5082_CR35","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s12936-019-2841-8","volume":"18","author":"J Raman","year":"2019","unstructured":"Raman J, Allen E, Workman L, Mabuza A, Swanepoel H, Malatje G, et al. Safety and tolerability of single low-dose primaquine in a low-intensity transmission area in South Africa: an open-label, randomized controlled trial. Malar J. 2019;18:209.","journal-title":"Malar J"},{"key":"5082_CR36","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s12936-020-03287-5","volume":"19","author":"LE Mhamilawa","year":"2020","unstructured":"Mhamilawa LE, Ngasala B, Morris U, Kitabi EN, Barnes R, Soe AP, et al. Parasite clearance, cure rate, post-treatment prophylaxis and safety of standard 3-day versus an extended 6-day treatment of artemether\u2013lumefantrine and a single low-dose primaquine for uncomplicated Plasmodium falciparum malaria in Bagamoyo district, Tanzania: a randomized controlled trial. Malar J. 2020;19:216.","journal-title":"Malar J"},{"key":"5082_CR37","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268820003167","volume":"149","author":"G Kishoyian","year":"2021","unstructured":"Kishoyian G, Njagi EN, Orinda GO, Kimani FT, Thiongo K, Matoke-Muhia D. Efficacy of artemisinin\u2013lumefantrine for treatment of uncomplicated malaria after more than a decade of its use in Kenya. Epidemiol Infect. 2021;149: e27.","journal-title":"Epidemiol Infect"},{"key":"5082_CR38","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/S1473-3099(21)00142-0","volume":"21","author":"A Uwimana","year":"2021","unstructured":"Uwimana A, Umulisa N, Venkatesan M, Svigel SS, Zhou Z, Munyaneza T, et al. Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study. Lancet Infect Dis. 2021;21:1120\u20138.","journal-title":"Lancet Infect Dis"},{"key":"5082_CR39","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12936-023-04574-7","volume":"22","author":"CO Falade","year":"2023","unstructured":"Falade CO, Orimadegun AE, Olusola FI, Michael OS, Anjorin OE, Funwei RI, et al. Efficacy and safety of pyronaridine-artesunate versus artemether-lumefantrine in the treatment of acute uncomplicated malaria in children in South-West Nigeria: an open-labelled randomized controlled trial. Malar J. 2023;22:154.","journal-title":"Malar J"},{"key":"5082_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1002729","volume":"8","author":"M Pinkevych","year":"2012","unstructured":"Pinkevych M, Petravic J, Chelimo K, Kazura JW, Moormann AM, Davenport MP. The dynamics of naturally acquired immunity to Plasmodium falciparum infection. PLoS Comput Biol. 2012;8: e1002729.","journal-title":"PLoS Comput Biol"},{"key":"5082_CR41","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12936-019-2647-8","volume":"18","author":"P Barua","year":"2019","unstructured":"Barua P, Beeson JG, Maleta K, Ashorn P, Rogerson SJ. The impact of early life exposure to Plasmodium falciparum on the development of naturally acquired immunity to malaria in young Malawian children. Malar J. 2019;18:11.","journal-title":"Malar J"},{"key":"5082_CR42","doi-asserted-by":"publisher","first-page":"558","DOI":"10.4269\/ajtmh.2003.69.558","volume":"69","author":"AA Djimde","year":"2003","unstructured":"Djimde AA, Doumbo OK, Traore O, Guindo AB, Kayentao K, Diourte Y, et al. Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria. Am J Trop Med Hyg. 2003;69:558\u201363.","journal-title":"Am J Trop Med Hyg"},{"key":"5082_CR43","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1086\/596741","volume":"199","author":"B Greenhouse","year":"2009","unstructured":"Greenhouse B, Slater M, Njama-Meya D, Nzarubara B, Maiteki-Sebuguzi C, Clark TD, et al. Decreasing efficacy of antimalarial combination therapy in Uganda is explained by decreasing host immunity rather than increasing drug resistance. J Infect Dis. 2009;199:758\u201365.","journal-title":"J Infect Dis"},{"key":"5082_CR44","volume-title":"Malaria: artemisinin partial resistance","author":"WHO","year":"2022","unstructured":"WHO. Malaria: artemisinin partial resistance. Geneva: World Health Organization; 2022."},{"key":"5082_CR45","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ijpddr.2021.09.005","volume":"17","author":"K K\u00fcmpornsin","year":"2021","unstructured":"K\u00fcmpornsin K, Loesbanluechai D, de Cozar C, Kotanan N, Chotivanich K, White NJ, et al. Lumefantrine attenuates Plasmodium falciparum artemisinin resistance during the early ring stage. Int J Parasitol Drugs Drug Resist. 2021;17:186\u201390.","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"5082_CR46","doi-asserted-by":"publisher","first-page":"e00002","DOI":"10.1128\/aac.00002-22","volume":"66","author":"G Tadele","year":"2022","unstructured":"Tadele G, Jaiteh FK, Oboh M, Oriero E, Dugassa S, Amambua-Ngwa A, et al. Persistence of residual submicroscopic P. falciparum parasitemia following treatment of artemether-lumefantrine in Ethio-Sudan Border Western Ethiopia. Antimicrob Agents Chemother. 2022;66:e00002-22.","journal-title":"Antimicrob Agents Chemother"},{"key":"5082_CR47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0176004","volume":"12","author":"M Teklemariam","year":"2017","unstructured":"Teklemariam M, Assefa A, Kassa M, Mohammed H, Mamo H. Therapeutic efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria in a high-transmission area in northwest Ethiopia. PLoS ONE. 2017;12: e0176004.","journal-title":"PLoS ONE"},{"key":"5082_CR48","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12936-022-04436-8","volume":"22","author":"K Gubae","year":"2023","unstructured":"Gubae K, Mohammed H, Sime H, Hailgiorgis H, Mare AK, Gidey B, et al. Safety and therapeutic efficacy of artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria at Shecha health centre, Arba Minch. Ethiopia Malar J. 2023;22:9.","journal-title":"Ethiopia Malar J"},{"key":"5082_CR49","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12936-018-2290-9","volume":"17","author":"E Davlantes","year":"2018","unstructured":"Davlantes E, Dimbu PR, Ferreira CM, Florinda Joao M, Pode D, F\u00e9lix J, et al. Efficacy and safety of artemether\u2013lumefantrine, artesunate\u2013amodiaquine, and dihydroartemisinin\u2013piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in three provinces in Angola, 2017. Malar J. 2018;17:144.","journal-title":"Malar J"},{"key":"5082_CR50","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2147\/TCRM.S127571","volume":"13","author":"T Deressa","year":"2017","unstructured":"Deressa T, Seid ME, Birhan W, Aleka Y, Tebeje BM. In vivo efficacy of artemether\u2013lumefantrine against uncomplicated Plasmodium falciparum malaria in Dembia District. Northwest Ethiopia Ther Clin Risk Manag. 2017;13:201\u20136.","journal-title":"Northwest Ethiopia Ther Clin Risk Manag"},{"key":"5082_CR51","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1186\/s12936-020-03376-5","volume":"19","author":"Y Wu","year":"2020","unstructured":"Wu Y, Soe MT, Aung PL, Zhao L, Zeng W, Menezes L, et al. Efficacy of artemether-lumefantrine for treating uncomplicated Plasmodium falciparum cases and molecular surveillance of drug resistance genes in Western Myanmar. Malar J. 2020;19:304.","journal-title":"Malar J"},{"key":"5082_CR52","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1086\/650301","volume":"201","author":"K Stepniewska","year":"2010","unstructured":"Stepniewska K, Ashley E, Lee SJ, Anstey N, Barnes KI, Binh TQ, et al. In vivo parasitological measures of artemisinin susceptibility. J Infect Dis. 2010;201:570\u20139.","journal-title":"J Infect Dis"},{"key":"5082_CR53","volume-title":"Global plan for artemisinin resistance containment (GPARC)","author":"WHO","year":"2011","unstructured":"WHO. Global plan for artemisinin resistance containment (GPARC). Geneva: World Health Organization; 2011."},{"key":"5082_CR54","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S1473-3099(15)70032-0","volume":"15","author":"KM Tun","year":"2015","unstructured":"Tun KM, Imwong M, Lwin KM, Win AA, Hlaing TM, Hlaing T, et al. Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker. Lancet Infect Dis. 2015;15:415\u201321.","journal-title":"Lancet Infect Dis"},{"key":"5082_CR55","unstructured":"Tadesse M. Therapeutic efficacy and safety of artemether-lumefantrine plus a single low-dose primaquine for the treatment of uncomplicated Plasmodium falciparum malaria at Maksegnit Health Center, Northwest Ethiopia. Thesis. Bahir Dar University, Ethiopia. 2023."},{"key":"5082_CR56","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.2147\/TCRM.S113603","volume":"12","author":"F Wudneh","year":"2016","unstructured":"Wudneh F, Assefa A, Desalegn Nega HM, Solomon H, Kebede T, Woyessa A, et al. Open-label trial on efficacy of artemether\/lumefantrine against the uncomplicated Plasmodium falciparum malaria in Metema district. Northwestern Ethiopia Ther Clin Risk Manag. 2016;12:1293.","journal-title":"Northwestern Ethiopia Ther Clin Risk Manag"},{"key":"5082_CR57","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s12936-015-0744-x","volume":"14","author":"YA Ebstie","year":"2015","unstructured":"Ebstie YA, Zeynudin A, Belachew T, Desalegn Z, Suleman S. Assessment of therapeutic efficacy and safety of artemether-lumefantrine (Coartem\u00ae) in the treatment of uncomplicated Plasmodium falciparum malaria patients in Bahir Dar district, Northwest Ethiopia: an observational cohort study. Malar J. 2015;14:236.","journal-title":"Malar J"},{"key":"5082_CR58","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1093\/infdis\/jiaa498","volume":"225","author":"K Stepniewska","year":"2022","unstructured":"Stepniewska K, Humphreys GS, Gon\u00e7alves BP, Craig E, Gosling R, Guerin PJ, et al. Efficacy of single-dose primaquine with artemisinin combination therapy on Plasmodium falciparum gametocytes and transmission: an individual patient meta-analysis. J Infect Dis. 2022;225:1215\u201326.","journal-title":"J Infect Dis"},{"key":"5082_CR59","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1186\/s12879-017-2530-6","volume":"17","author":"J Zwang","year":"2017","unstructured":"Zwang J, D\u2019Alessandro U, Ndiaye J-L, Djimd\u00e9 AA, Dorsey G, M\u00e5rtensson AA, et al. Haemoglobin changes and risk of anaemia following treatment for uncomplicated falciparum malaria in sub-Saharan Africa. BMC Infect Dis. 2017;17:443.","journal-title":"BMC Infect Dis"},{"key":"5082_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1756-3305-3-1","volume":"3","author":"A Assefa","year":"2010","unstructured":"Assefa A, Kassa M, Tadese G, Mohamed H, Animut A, Mengesha T. Therapeutic efficacy of artemether\/lumefantrine (Coartem\u00ae) against Plasmodium falciparum in Kersa. South West Ethiopia Parasit Vectors. 2010;3:1.","journal-title":"South West Ethiopia Parasit Vectors"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-024-05082-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-024-05082-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-024-05082-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T11:04:52Z","timestamp":1725015892000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-024-05082-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,30]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5082"],"URL":"https:\/\/doi.org\/10.1186\/s12936-024-05082-y","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,30]]},"assertion":[{"value":"31 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A letter of ethical clearance was obtained from the ethical review committee of the School of Biomedical and Laboratory Sciences, College of Medicine and Health Science, University of Gondar (Ref. No. SBLS\/398\/2022), and written informed consent and\/or assent was obtained from all study participants. Verbal consent was also obtained for the pregnancy test. A transport reimbursement was provided to all the study participants. This trial has been registered retrospectively at  as PACTR202309773069812 on September 1, 2023.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"266"}}